In the quest to outshine the broader market, stock pickers diligently seek out stocks with the potential for superior performance. Making the right choices can significantly elevate your wealth.
After finishing at $15.91 in the prior trading day, Adma Biologics Inc (NASDAQ: ADMA) closed at $16.03, up 0.75%. In other words, the price has increased by $0.75 from its previous closing price. On the day, 3.18 million shares were traded. ADMA stock price reached its highest trading level at $16.04 during the session, while it also had its lowest trading level at $15.68.
Ratios:
Our goal is to gain a better understanding of ADMA by taking a closer look at its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 42.37 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 58.16. For the most recent quarter (mrq), Quick Ratio is recorded 2.78 and its Current Ratio is at 5.33. In the meantime, Its Debt-to-Equity ratio is 0.21 whereas as Long-Term Debt/Eq ratio is at 0.21.
On October 13, 2022, Mizuho started tracking the stock assigning a Buy rating and target price of $5. Raymond James Upgraded its Outperform to Strong Buy on November 11, 2021, while the target price for the stock was maintained at $5.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Sep 15 ’25 when Grossman Adam S sold 21,000 shares for $16.13 per share. The transaction valued at 338,730 led to the insider holds 2,025,850 shares of the business.
Grossman Adam S sold 21,000 shares of ADMA for $354,480 on Aug 15 ’25. The President and CEO now owns 2,031,850 shares after completing the transaction at $16.88 per share. On Jul 15 ’25, another insider, Grossman Adam S, who serves as the President and CEO of the company, sold 21,000 shares for $18.66 each. As a result, the insider received 391,860 and left with 2,037,850 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ADMA now has a Market Capitalization of 3825250560 and an Enterprise Value of 3818790400. As of this moment, Adma’s Price-to-Earnings (P/E) ratio for their current fiscal year is 18.87, and their Forward P/E ratio for the next fiscal year is 18.08. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 0.61. For the stock, the TTM Price-to-Sale (P/S) ratio is 8.07 while its Price-to-Book (P/B) ratio in mrq is 9.63. Its current Enterprise Value per Revenue stands at 8.054 whereas that against EBITDA is 23.349.
Stock Price History:
The Beta on a monthly basis for ADMA is 0.48, which has changed by -0.1689995 over the last 52 weeks, in comparison to a change of 0.1675967 over the same period for the S&P500. Over the past 52 weeks, ADMA has reached a high of $25.67, while it has fallen to a 52-week low of $13.50. The 50-Day Moving Average of the stock is -6.78%, while the 200-Day Moving Average is calculated to be -12.81%.
Shares Statistics:
The stock has traded on average 3.25M shares per day over the past 3-months and 3657590 shares per day over the last 10 days, according to various share statistics. A total of 239.38M shares are outstanding, with a floating share count of 230.45M. Insiders hold about 3.43% of the company’s shares, while institutions hold 88.99% stake in the company. Shares short for ADMA as of 1756425600 were 14977531 with a Short Ratio of 4.61, compared to 1753920000 on 13736123. Therefore, it implies a Short% of Shares Outstanding of 14977531 and a Short% of Float of 7.71.
Earnings Estimates
Its stock is currently analyzed by 2.0 different market analysts. The consensus estimate for the next quarter is $0.18, with high estimates of $0.18 and low estimates of $0.18.
Analysts are recommending an EPS of between $0.59 and $0.54 for the fiscal current year, implying an average EPS of $0.56. EPS for the following year is $0.93, with 3.0 analysts recommending between $0.97 and $0.87.
Revenue Estimates
3 analysts predict $131.2M in revenue for the current quarter. It ranges from a high estimate of $133.3M to a low estimate of $130.1M. As of the current estimate, Adma Biologics Inc’s year-ago sales were $119.84MFor the next quarter, 3 analysts are estimating revenue of $137.17M. There is a high estimate of $139.8M for the next quarter, whereas the lowest estimate is $133.5M.
A total of 4 analysts have provided revenue estimates for ADMA’s current fiscal year. The highest revenue estimate was $509.61M, while the lowest revenue estimate was $503.5M, resulting in an average revenue estimate of $506.3M. In the same quarter a year ago, actual revenue was $426.45MBased on 4 analysts’ estimates, the company’s revenue will be $637.85M in the next fiscal year. The high estimate is $647.21M and the low estimate is $631M.
